Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oroxylin A and PD-1/PD-L1 inhibitor in preparation of medicine for treating liver cancer

A PD-L1, PD-1 technology, applied in the field of medicine, can solve problems such as statistically significant differences

Inactive Publication Date: 2021-11-19
CHINA PHARM UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the results of Bristol-Myers Squibb's phase III clinical trial (CheckMate-459) on the treatment of advanced liver cancer with PD-1 antibody (nivolumab) showed that the overall survival of the PD-1 antibody treatment group was significantly higher than that of the first-line liver cancer clinical drug sorafenib. No statistically significant difference between groups

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oroxylin A and PD-1/PD-L1 inhibitor in preparation of medicine for treating liver cancer
  • Application of oroxylin A and PD-1/PD-L1 inhibitor in preparation of medicine for treating liver cancer
  • Application of oroxylin A and PD-1/PD-L1 inhibitor in preparation of medicine for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] In this example, by constructing a mouse liver cancer cell H22 subcutaneous xenograft model, it was found that the combination of melaleucain and PD-1 / PD-L1 inhibitors can effectively inhibit tumor growth and significantly prolong the survival period of animals without affecting the body weight of experimental animals. produced a significant inhibitory effect.

[0016] 1. Experimental materials

[0017] 1.1 Test drugs

[0018] Name: Melaleuca paper

[0019] Content: 99.52%

[0020] Provider: School of Pharmacy, China Pharmaceutical University

[0021] Preparation method: the crude drug of melaleucain was jet-milled and dispersed in 0.5% CMC-Na, the concentration of the prepared drug was 15mg / mL, and the administration volume was 0.4mL / 20g, that is, the administration concentration was 300mg / Kg.

[0022] 1.2 Small molecule inhibitors of PD-1 / PD-L1

[0023] Name: BMS-1

[0024] Manufacturer: MedChemExpress

[0025] Specification: 10mg

[0026] Preparation method: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of oroxylin A and a PD-1 / PD-L1 inhibitor in preparation of a medicine for treating liver cancer, and belongs to the technical field of medicines. According to the application disclosed by the invention, an experiment of treating mouse liver cancer cell H22 subcutaneous transplantation tumor by combining the oroxylin A with the PD-1 / PD-L1 inhibitor proves that the combination of the oroxylin A with the PD-1 / PD-L1 small-molecule inhibitor or the PD-1 monoclonal antibody can obviously improve the anti-tumor effect of independent use of the oroxylin, the PD-1 / PD-L1 small-molecule inhibitor and the PD-1 monoclonal antibody, an obvious inhibition effect on the weight of an experimental animal is not generated, and more importantly, the survival time of tumor-bearing mice is obviously prolonged. Therefore, the oroxylin A can promote the curative effect of the immune checkpoint inhibitor on the liver cancer, and the combined medication mode can play a great role in the future liver cancer treatment.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of safflower paper and PD-1 / PD-L1 inhibitors in the preparation of drugs for treating liver cancer. Background technique [0002] Oroxylin A is one of the active components of Scutellaria baicalensis. It has obvious antitumor effect and is a natural antitumor drug with broad application prospects. However, the pharmacological effects of kelciene are extensive, and the mechanism of its anti-tumor effect has not yet been fully elucidated. The literature shows that celestein can exert its anti-tumor effect by inducing tumor cell apoptosis, and also has the effect of inhibiting the growth of tumor blood vessels. At the same time, the anti-cancer effect of celesteol is different from that of general chemotherapy and anti-cancer drugs. It can selectively kill tumor cells and has little effect on the normal hematopoietic system, which is not available in cur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/352A61K39/395A61P1/16A61P35/00
CPCA61K31/352A61K45/06A61K39/3955A61P35/00A61P1/16A61K2300/00
Inventor 张小博郭青龙周煜新杨林王佩文
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com